SG Americas Securities LLC Buys Shares of 14,555 Chimerix, Inc. (NASDAQ:CMRX)

SG Americas Securities LLC bought a new stake in Chimerix, Inc. (NASDAQ:CMRXGet Rating) during the 2nd quarter, Holdings Channel reports. The fund bought 14,555 shares of the biopharmaceutical company’s stock, valued at approximately $30,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Clear Harbor Asset Management LLC raised its position in shares of Chimerix by 293.5% during the second quarter. Clear Harbor Asset Management LLC now owns 61,000 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 45,500 shares during the period. Integral Health Asset Management LLC grew its holdings in shares of Chimerix by 8.2% during the first quarter. Integral Health Asset Management LLC now owns 119,000 shares of the biopharmaceutical company’s stock worth $545,000 after buying an additional 9,000 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Chimerix during the first quarter worth about $636,000. Philosophy Capital Management LLC bought a new position in shares of Chimerix during the first quarter worth about $2,888,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Chimerix by 74.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 623,668 shares of the biopharmaceutical company’s stock worth $1,297,000 after buying an additional 266,195 shares in the last quarter. Institutional investors and hedge funds own 63.43% of the company’s stock.

Chimerix Stock Down 0.5 %

CMRX stock opened at $2.21 on Friday. The business has a 50 day moving average price of $1.93 and a two-hundred day moving average price of $2.19. The company has a market cap of $194.58 million, a price-to-earnings ratio of 1.26 and a beta of 1.08. Chimerix, Inc. has a twelve month low of $1.27 and a twelve month high of $7.42.

Insider Buying and Selling at Chimerix

In other Chimerix news, Director Fred A. Middleton bought 20,000 shares of Chimerix stock in a transaction dated Thursday, September 29th. The stock was bought at an average cost of $1.86 per share, for a total transaction of $37,200.00. Following the purchase, the director now owns 40,000 shares of the company’s stock, valued at approximately $74,400. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 8.20% of the company’s stock.

Analysts Set New Price Targets

CMRX has been the subject of a number of research reports. StockNews.com upgraded Chimerix from a “hold” rating to a “buy” rating in a report on Friday, November 4th. Capital One Financial initiated coverage on Chimerix in a research note on Wednesday, September 7th. They issued an “overweight” rating and a $7.00 price target for the company. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $9.60.

Chimerix Profile

(Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Featured Stories

Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRXGet Rating).

Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.